{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-22-000065","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.874341+00:00","generated_at":"2026-06-22T23:40:21.579169+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q3 sales $680.8M (-8.9% YoY); non-GAAP EPS $2.60 vs $3.71; FY22 guidance reaffirmed","bullets":["Q3 net sales $680.8M, down 8.9% YoY; currency-neutral core sales (ex-COVID and legal settlements) grew 6.1%.","GAAP net loss $164.2M ($5.52 loss per diluted share) vs income $3,928M in Q3 2021, driven by Sartorius fair-value swings.","Non-GAAP net income $77.9M ($2.60 diluted EPS) vs $112.2M ($3.71) in Q3 2021.","Life Science segment sales $317.9M (-14.9% YoY); Clinical Diagnostics $361.9M (-2.8% YoY; +3.0% currency-neutral).","FY22 guidance: non-GAAP currency-neutral revenue growth at high end of prior 1.0-2.0%; COVID revenue now ~$105M; operating margin ~19.0%."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-22-000065","json":"https://secwatch.observer/filing/0000012208-22-000065.json","markdown":"https://secwatch.observer/filing/0000012208-22-000065.md","text":"https://secwatch.observer/filing/0000012208-22-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/0000012208-22-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/bio-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:40:21.579169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89e1f453010f5989b41a76177c3a55c2099326fb","claim":"BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2022 results: revenue $680.8 million, net income $164.2 million, or a loss of $5.52 per share, on a diluted basis.","evidence_excerpt":"in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent compared to $747.0 million reported for the third quarter of 2021. COVID-related revenue was approximately $17 million in the third quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/0000012208-22-000065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$680.8 million"},{"label":"Net income","value":"$164.2 million, or a loss of $5.52 per share, on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}